Follicular Lymphoma
Follicular Lymphoma
The latest news, research, and perspectives in follicular lymphoma (FL).
Advertisement
Melissa BadamoFollicular Lymphoma | July 8, 2025
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Melissa BadamoAcute Lymphoblastic Leukemia | July 7, 2025
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Nichole TuckerFollicular Lymphoma | June 27, 2025
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
Melissa BadamoFollicular Lymphoma | June 25, 2025
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
Izzah NawazFollicular Lymphoma | June 13, 2025
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
Andrew MorenoMeeting News | June 5, 2025
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Advertisement
Melissa BadamoFollicular Lymphoma | June 3, 2025
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Andrew MorenoMeeting News | June 1, 2025
A phase 2/3 trial is evaluating zilovertamab vedotin plus rituximab and gemcitabine-oxaliplatin in relapsed/refractory DLBCL.
Melissa BadamoAggressive B-Cell Lymphoma | May 27, 2025
Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.
Andrew MorenoAggressive B-Cell Lymphoma | May 23, 2025
The global phase 3 RCT is part of an sBLA for glofitamab plus gemcitabine and oxaliplatin use in R/R DLBCL NOS.
Nichole TuckerTransplantation & Cellular Therapy | May 29, 2025
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Andrew MorenoAggressive B-Cell Lymphoma | April 30, 2025
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Melissa BadamoPrint | April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHPTransplantation & Cellular Therapy | April 15, 2025
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Melissa BadamoVideo Insights | April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Advertisement
Advertisement